Certificate of Analysis and Data Sheet

Source:
Human

Catalog No.
PRO-339

Background :

Thrombin is the final protease in the blood coagulation cascade and serves both pro- and anticoagulant functions through the cleavage of several targets. The ability of thrombin to specifically recognize a wide range of substrates derives from interactions which occur outside of the active site of thrombin. Thrombin possesses two anion binding exosites which mediate many of its interactions with cofactors and substrates, and although many structures of thrombin have been solved, few such interactions have been described in molecular detail. Glycosaminoglycan binding to exosite II of thrombin plays a major role in switching off the procoagulant functions of thrombin by mediating its irreversible inhibition by circulating serpins and by its binding to the endothelial cell surface receptor thrombomodulin.

Physical Appearance:

Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation:

Thrombin, at a concentration of 0.5mg/ml, was dialyzed against 5mM sodium citrate, 0.01% PEG, and 0.02M NaCl pH 6.5 before lyophilization.

Solubility:

It is recommended to reconstitute the lyophilized Thrombin in sterile 18MO-cm H2O not less than 100ug/ml, which can then be further diluted to other aqueous solutions.

Stability:

Lyophilized Thrombin,although stable at room temperature for 3 weeks, should be stored desiccated below -18 C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).
Please avoid freeze-thaw cycles.

Purity:

Greater than 95.0% as determined by:
(a) Analysis by RP-HPLC.
(b) Anion-exchange FPLC.
(c) Analysis by reducing and non-reducing SDS-PAGE Silver Stained gel.

Dimers and aggregates:

Less than 1% as determined by silver-stained SDS-PAGE gel analysis.

Biological Activity:

ProSpec's Thrombin is fully biologically active when compared to standard. The potency per mg was tested and found to be 2000Units/mg.

Endotoxin:

Less than 0.1 ng/ug (IEU/ug) of Thrombin.

Usage:

This material is offered by ProSpec-TechnoGene for research, laboratory or further evaluation purposes.

Latest Publications:

1. Injections of blood, thrombin, and plasminogen more severely damage neonatal mouse brain than mature mouse brain.
Brain Pathol 2005 Oct;15(4):273-80
2. Percutaneous thrombin injection to treat a post-traumatic hepatic pseudoaneurysm.
J Trauma 2005 Oct;59(4):1022-4
3. Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Thromb Haemost 2005 Nov;94(5):958-64
4. Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms.
Immunobiology 2005;210(10):781-8
5. Inhibition of neutrophil elastase and thrombin activity by caffeic acid esters.
Pharmazie 2005 Nov;60(11):869-73
6. Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products.
Diab Vasc Dis Res 2005 May;2(2):81-7